Table 2.
Baseline demographic and clinical characteristics of the enrolled population
|
Characteristic |
Placebo (n=88) |
Apremilast BID |
Total (N=352) |
||
|---|---|---|---|---|---|
| 10 mg (n=89) | 20 mg (n=87) | 30 mg (n=88) | |||
| Age (years) |
44.1 ± 13.7 |
44.4 ± 14.0 |
44.6 ± 12.6 |
44.1 ± 14.7 |
44.3 ± 13.7 |
| Male |
53 (60.2) |
63 (70.8) |
55 (63.2) |
50 (56.8) |
221 (62.8) |
| Race |
|
|
|
|
|
| White |
83 (94.3) |
82 (92.1) |
82 (94.3) |
80 (90.9) |
327 (92.9) |
| Black |
1 (1.1) |
2 (2.2) |
1 (1.1) |
2 (2.3) |
6 (1.7) |
| Asian |
4 (4.5) |
3 (3.4) |
2 (2.3) |
4 (4.5) |
13 (3.7) |
| Other |
0 (0.0) |
2 (2.2) |
2 (2.3) |
2 (2.3) |
6 (1.7) |
| Height (cm) |
171.2 ± 8.6 |
171.5 ± 10.2 |
171.7 ± 9.6 |
171.2 ± 10.7 |
171.5 ± 9.6 |
| Weight (kg) |
90.3 ± 21.4 |
95.7 ± 23.2 |
89.9 ± 20.2 |
91.2 ± 23.1 |
91.8 ± 22.0 |
| BMI (kg/m2) |
30.8 ± 6.7 |
32.5 ± 7.4 |
30.4 ± 6.2 |
31.1 ± 7.8 |
31.2 ± 7.1 |
| Total PASI score |
18.1 ± 5.7 |
18.1 ± 6.3 |
18.5 ± 7.3 |
19.1 ± 7.1 |
18.5 ± 6.6 |
| BSA |
21.0 ± 11.2 |
21.3 ± 11.4 |
20.7 ± 12.4 |
25.0 ± 15.4 |
22.0 ± 12.8 |
| + History PsA |
17 (19.3) |
20 (22.5) |
16 (18.4) |
21 (23.9) |
74 (21.0) |
| Plaque psoriasis history (years) |
19.6 ± 11.6 |
18.0 ± 12.4 |
19.2 ± 12.2 |
19.2 ± 12.0 |
19.0 ± 12.0 |
| Previous systemic therapy for psoriasis | 39 (44.3) | 47 (52.8) | 43 (49.4) | 47 (53.4) | 176 (50.0) |
Values are mean ± SD or n (%). BMI, body mass index; BSA, body surface area; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis.